Werewolf Therapeutics (NASDAQ:HOWL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) issued its earnings results on Tuesday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

Werewolf Therapeutics Stock Up 0.4 %

Shares of NASDAQ HOWL traded up $0.01 during mid-day trading on Thursday, hitting $1.24. 66,302 shares of the stock traded hands, compared to its average volume of 266,072. Werewolf Therapeutics has a 52 week low of $1.03 and a 52 week high of $6.89. The stock has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.82. The company has a market cap of $55.04 million, a price-to-earnings ratio of -0.81 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10.

Analyst Upgrades and Downgrades

HOWL has been the topic of a number of analyst reports. JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.